A Strong
Start
For Superior
Survival1,2
5-Year OS Data
Available
VYXEOS demonstrated superior efficacy with longer overall survival and higher CR and CR+CRi rates compared to traditional chemotherapya and provided an improved opportunity for transplant1,2
Median overall survivalb (primary endpoint) of 9.6 months with VYXEOS vs 5.9 months with 7+3 (HR=0.69 [95% CI: 0.52, 0.90], P=0.005c).1 Rate of CR was 38% with VYXEOS vs 26% with 7+3; rate of CR+CRi was 48% with VYXEOS vs 33% with 7+3.1,2 Overall rate of HSCTd was 35% with VYXEOS vs 25% with 7+33,e
In a Phase 3, randomized, multicenter, open-label, active-controlled superiority study of VYXEOS vs 7+3 (cytarabine and daunorubicin) in 309 patients (aged 60-75) with newly-diagnosed t-AML or AML-MRC1 See full study design
See VYXEOS long-term
estimated survival data
VYXEOS LONG-TERM OS DATA
Overall survival is more than double at 5 years with VYXEOS (18%) vs 7+3 (8%) based on KM estimates1,3
National Comprehensive Cancer Network® (NCCN®) recommendations
Liposomal daunorubicin and cytarabine (VYXEOS) is the ONLY treatment recommended by NCCN for induction in sAML patients ≥60 years4
Outpatient administration
Inpatient and outpatient administration options for appropriate patients
Group purchasing organization
VYXEOS is now partnering with certain group purchasing organizations
- 7+3: cytarabine 100 mg/m2 and daunorubicin 60 mg/m2.1
- Overall survival was defined as date of randomization to death from any cause.1
- P value is 2-sided.1
- First CR, induction failure, or as salvage after relapse.1
- In the primary analysis of the Phase 3 trial, the overall rate of HSCT (first CR, induction failure, or as salvage after relapse) was 34% (52/153) in the VYXEOS arm and 25% (39/156) in the control arm.1
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.